Everand Logo

Welcome to Everand!

  • STAT

    Bristol claims victory in crucial immunotherapy trial, but results raise some questions

    by Adam Feuerstein Feb 05, 2018 2 minutes
    Source: Mel Evans/AP

    Bristol-Myers Squibb reported positive results Monday in a crucial immunotherapy trial, using a combination of the two drugs Opdivo and Yervoy to treat patients with a specific type of non-small cell lung cancer patients.

    But previously undisclosed changes made by Bristol to the study, known as Checkmate-227, are raising questions about the validity and strength of the

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Roche Obesity Drug, An Experimental Lilly Insulin, And More
    Roche disclosed that its recently acquired experimental obesity medication helped people lose a significant amount of weight in a Phase 1 trial.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.

    Related